openPR Logo
Press release

Common Warts Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight

09-02-2025 09:38 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Common Warts Pipeline 2025: In-depth Clinical Trials Analysis

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Common Warts pipeline constitutes 5+ key companies continuously working towards developing 5+ Common Warts treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Common Warts Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Common Warts Market.

The Common Warts Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Common Warts Pipeline Report: https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Common Warts treatment therapies with a considerable amount of success over the years.
• Common Warts companies working in the treatment market are Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others, are developing therapies for the Common Warts treatment
• Emerging Common Warts therapies in the different phases of clinical trials are- CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others are expected to have a significant impact on the Common Warts market in the coming years.
• In May 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced progress in its late-stage development pipeline, highlighted by the completion of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for VP-315, the company's investigational treatment for basal cell carcinoma. Additionally, Verrica is making strides toward launching a global Phase 3 clinical program for VP-102/YCANTH, its treatment candidate for common warts, in collaboration with its partner, Torii Pharmaceutical.
• In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company headquartered in San Diego, announced the successful enrollment of the final participant in its Phase 3 clinical trial, CFW-3A. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. It's important to note that CANDIN is not yet approved for this indication.
• In December 2024, Veradermics was a late-stage clinical biopharmaceutical company specializing in aesthetics and dermatology, dedicated to developing innovative therapies for common skin disorders. Its leading product, VDPHL01, is a non-hormonal oral treatment currently being tested for androgenetic alopecia (AGA) and pattern hair loss (PHL) in both male and female patients. Additionally, the company's pipeline features treatments targeting widespread dermatological conditions like warts and molluscm contagiosum.
• In August 2024, Verrica Pharmaceuticals reported encouraging new findings from its Phase 2 trial of the oncolytic peptide VP-315 for basal cell carcinoma treatment. With positive safety and efficacy outcomes, the company sees VP-315 as a potential first-line therapy for this cancer type. Comprehensive results will be shared at an upcoming KOL event. Furthermore, Verrica has revised its agreement with Torii Pharmaceutical Inc. Ltd., supporting the progression of YCANTH into Phase 3 trials for common warts. Addressing a significant unmet need in dermatology, YCANTH has the potential to become a new standard of care, as no FDA-approved treatments currently exist for common warts.
• In May 2024, Verrica Pharmaceuticals announced an update to its collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to jointly fund the global Phase 3 clinical trial for YCANTH® targeting common warts. According to the revised terms, both companies will equally share the trial expenses, with Torii covering Verrica's share by offsetting future payments related to regulatory milestones and sales of YCANTH for molluscm contagiosum and common warts in Japan. Furthermore, Torii will make an $8.0 million milestone payment to Verrica upon dosing the first patient in Japan, with the Phase 3 trial expected to commence in the first half of 2025.

Common Warts Overview
Common warts are small, noncancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, or other areas prone to minor cuts and abrasions. Common warts have a rough, grainy texture and are often flesh-colored, with tiny black dots (clotted blood vessels) on the surface.

Get a Free Sample PDF Report to know more about Common Warts Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Common Warts Drugs Under Different Phases of Clinical Development Include:
• CANDIN: Nielsen BioSciences/Maruho
• VP-102: Verrica Pharmaceutical
• FIT039: Kino Pharma/ Iwaki Pharmaceutical
• A-101: Aclaris Therapeutics, Inc.
• KNP2002: KinoPharma Inc.
• 10% EISO: ViroXis Corporation
• CLS006: Maruho Co., Ltd.
• VDMN-21: Veradermics, Inc.
• Resiquimod: Graceway Pharmaceuticals, LLC
• Imiquimod: MEDA Pharma
• Picato: LEO Pharma

Common Warts Route of Administration
Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Common Warts Molecule Type
Common Warts Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Common Warts Pipeline Therapeutics Assessment
• Common Warts Assessment by Product Type
• Common Warts By Stage and Product Type
• Common Warts Assessment by Route of Administration
• Common Warts By Stage and Route of Administration
• Common Warts Assessment by Molecule Type
• Common Warts by Stage and Molecule Type

DelveInsight's Common Warts Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Common Warts product details are provided in the report. Download the Common Warts pipeline report to learn more about the emerging Common Warts therapies
https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Common Warts Therapeutics Market include:
Key companies developing therapies for Common Warts are - Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Aclaris Therapeutics, and others.

Common Warts Pipeline Analysis:
The Common Warts pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Common Warts with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Common Warts Treatment.
• Common Warts key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Common Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Common Warts market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Common Warts drugs and therapies
https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Common Warts Pipeline Market Strengths
• The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes.
• An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years.

Common Warts Pipeline Market Opportunities
• Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously.
• Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness

Scope of Common Warts Pipeline Drug Insight
• Coverage: Global
• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
• Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies
• Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Common Warts Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight here

News-ID: 4167101 • Views:

More Releases from DelveInsight Business Research

Acanthamoeba Keratitis Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight
Acanthamoeba Keratitis Market Dynamics Indicate Upward Trajectory Through 2034, …
The Acanthamoeba Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acanthamoeba Keratitis pipeline products will significantly revolutionize the Acanthamoeba Keratitis market dynamics. DelveInsight's "Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United
Anticoagulants Market Positioned for Accelerated Development Through 2030, DelveInsight Finds
Anticoagulants Market Positioned for Accelerated Development Through 2030, Delve …
DelveInsight's *Anticoagulants Market Insights, Competitive Landscape, and Market Forecast - 2030* report provides a comprehensive analysis of anticoagulants, along with historical and projected market trends worldwide, covering North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The latest healthcare forecast report provides an in-depth analysis of Anticoagulants, offering comprehensive insights into the Anticoagulants revenue trends, prevalence, and treatment landscape. The report delves into key Anticoagulants statistics, highlighting the
Microvascular Angina Market to Experience Notable Growth in Forecast Span, DelveInsight Predicts
Microvascular Angina Market to Experience Notable Growth in Forecast Span, Delve …
DelveInsight's "Microvascular Angina Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Microvascular Angina, historical and forecasted epidemiology as well as the Microvascular Angina market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Microvascular Angina, offering comprehensive insights into the Microvascular Angina revenue trends, prevalence, and treatment landscape. The
Exocrine Pancreatic Insufficiency Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Exocrine Pancreatic Insufficiency Market Insights Highlight Expanding Outlook Ti …
DelveInsight's "Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Exocrine Pancreatic Insufficiency, historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Exocrine Pancreatic Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Exocrine Pancreatic Insufficiency Market

All 5 Releases


More Releases for Common

Common Problems in AODD Pump
Air Passing Without Pump Movement The pump fails to cycle, and compressed air passes directly through the exhaust without actuating the diaphragms. This often indicates internal valve or spool malfunction. Chemical Leakage from the Air Side Leakage observed from the exhaust or air side can be due to diaphragm rupture, allowing process fluid to mix with the air chamber. Poor or No Suction (Negative Suction Failure) The pump may struggle to self-prime or generate enough
Electrical Common Mode Chokes Market
Electrical Common Mode Chokes Market Overview Electrical common mode chokes consist of two or more coils of insulated wire on a single magnetic core. Each winding is put in series with one of the conductors. This means that the magnetic fields of the wires combine to present high impedance to the noise signal. This report provides a deep insight into the global Electrical Common Mode Chokes market covering all its essential aspects.
Common Warts Treatment Market - Winning the Battle Against Common Warts: Leading …
Newark, New Castle, USA: The "Common Warts Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Common Warts Treatment Market: https://www.growthplusreports.com/report/common-warts-treatment-market/8672 This latest report researches the industry structure,
Equip robots with common sense
In the future, a new generation of autonomous robots is set to complete tasks autonomously, even if something unforeseeable happens. With the support of the Austrian Science Fund FWF, information technology experts in Graz are working to advance the development of artificial intelligence and equip robots with common sense. Something that children learn through play and that adults are able to do on the basis of past experience, such as
Alzheimer’s, Arthritis & Heart Disease - Research Reveals: Common Cause, Commo …
Aneby, Sweden, (Ekotopia) – Sept. 14, 2011 - Researchers in dozens of countries have largely confirmed the original thesis of cardiologist Kurt A. Oster, M.D. and Fairfield University professor Donald J. Ross, Ph.D. about the enzyme XO in homogenized milk triggering atherosclerosis, chest pain, heart attacks, non-healing wounds, gout, psoriasis and multiple sclerosis. In fact, XO is now thought to be behind more than 50 chronic degenerative diseases. According to the
Common Work at Home Jobs
Working from home spells out a lot of difference when you want to get a no hassle less stressful job. Different jobs online have been posted to cater to the demand of companies who are looking for outsourced professionals to do these tasks for them from different work aspects. Online jobs mostly cater to technology and internet marketing resources that need to be worked upon. In these cases, companies found